Long-term follow-up data is the real determinant of the efficacy of novel therapies. Here, Robert Jones, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, discusses what the promising 2-year follow-up data from the KEYNOTE-045 trial of pembrolizumab for advanced urothelial cancer (NCT02256436) tells us moving forwards. Prof. Jones contemplates the indications and patients in which pembrolizumab may be used, as well as those where it wouldnt provide a significant benefit. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.
What does the 2-year follow-up tell us about the use of pembrolizumab for advanced bladder cancer?
